Here are the top 5 biosimilar articles for the week of July 3, 2023.
Hi, I’m Justina Petrullo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of July 3rd, 2023.
Number 5: It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.
Number 4: Celltrion USA launched its fifth biosimilar in the United States, Yuflyma (adalimumab-aaty), a biosimilar referencing Humira that is also 1 of 8 adalimumab products expected to launch in July.
Number 3: In his latest column, Sarfaraz K. Niazi, PhD, took a look at common misconceptions about biosimilar development and expressed how companies can seize new opportunities to save the US biosimilar market and generate profit.
Number 2: The Center for Biosimilars® provided an updated look on the adalimumab biosimilars that are coming down the US pipeline as well as what stakeholders need to know and how they can prepare ahead of the US launch of 8 adalimumab biosimilars in July 2023.
Number 1: After years of waiting and legal battles, the first of the 8 adalimumab biosimilars expected to launch in July 2023 have entered the market.
To read all of these articles and more, visit centerforbiosimilars.com.